Black Diamond Therapeutics (BDTX) Operating Leases (2020 - 2026)

Black Diamond Therapeutics (BDTX) has reported Operating Leases for 7 consecutive years, with $13.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 22.83% year-over-year to $13.1 million; the trailing twelve-month figure through Jun 2026 stood at $13.1 million (down 22.83% YoY), and the FY2025 full-year result was $15.1 million, down 19.77% from the prior year.
• Operating Leases slipped to $13.1 million in Q2 2026 per BDTX's latest filing, from $14.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $28.8 million in Q2 2022 and bottomed at $13.1 million in Q2 2026.
• Historically, Operating Leases has averaged $22.0 million across 5 years, with a median of $23.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 94.01% in 2022, then sank 30.28% in 2025.
• Over 5 years, Operating Leases stood at $25.3 million in 2022, then fell by 12.31% to $22.2 million in 2023, then dropped by 15.34% to $18.8 million in 2024, then retreated by 19.77% to $15.1 million in 2025, then retreated by 13.09% to $13.1 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $13.1 million, $14.1 million, and $15.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.